Theranostics Health (THX)

Theranostics Health, LLC (THX) is a pioneer in the next stage of molecular medicine: the blending of therapeutics and diagnostics to make personalized patient treatment a reality. The technology developed by the company represents a new paradigm in molecular medicine where the biomarker that services as the diagnostic is also the therapeutic target and the activity of actual protein drug targets in a patient’s tissue sample can be measured.

The breakthrough reverse phase protein microarray (RPMA) technology directly measures the activity of large numbers of protein drug targets and profiles the cellular circuitry of signaling pathways, allowing pharmaceutical developers to accurately assess the effectiveness of their proprietary drugs and physicians to tailor optimized personalized therapies to their patients. Since most molecularly targeted drug inhibitors now being developed act on protein targets, technologies such as those developed by Theranostics Health, that directly measure the state of drug targets, offer researchers significant advantages.

Phosphoproteomics for Personalized Medicine:

  • Theranostics Health’s proprietary reverse phase protein microarray (RPMA) technology directly measures the activity of phosphorylated protein drug targets and profiles the cellular circuitry of signaling pathways
  • THX technology is already being used to help pharmaceutical developers accurately assess the effectiveness of their proprietary drugs, a capability that can identify patients most likely to respond to specific drugs and decrease time and cost of drug development and clinical trials
  • THX technology shows strong potential for application to a wide range of uses including heart disease, diabetes, obesity, neurological disorders, and various inflammatory and infectious indications
  • THX technology positions the company at the center of the coming companion diagnostic (Rx/Dx) revolution
  • THX will begin offering clinical oncology services in 2008, allowing physicians to customize chemotherapy to the unique molecular profile of each patient’s tumor
  • THX technology and services make personalized patient treatment a reality